OptiScanner (OptiScan Biomedical) study shows clinical accuracy in monitoring blood glucose in Critically Ill ICU patients

New results demonstrate clinical accuracy for the OptiScanner, from OptiScan Biomedical Corp, in monitoring the blood glucose levels in critically ill ICU patients. Data presented from the MANAGE Study included results from a total of 63 critically ill medical and surgical ICU patients. Using Clarke Error Grid (CEG) analysis, 94.2 percent of the OptiScanner patient test results appeared in the grid's A zone with the remaining 5.8 percent falling in the B zone. CEG is considered the gold standard for assessing the accuracy of glucose measurement devices, with the grid's zone A representing results that are the most clinically accurate and results in zone B considered clinically acceptable. This is the fourth clinical study to evaluate the glucose monitoring accuracy of the OptiScanner and the first to do so with the final configuration of the OptiScanner in critically ill ICU patients. These results, presented by Marcus J. Schultz, Academic Medical Center at the University of Amsterdam, at the 32nd International Symposium on Intensive Care and Emergency Medicine, are consistent with previous findings. The OptiScanner received CE Mark certification for use in the European Union in September 2011 and the company plans to launch the product in Europe in the next few months.